George Porter
| Title | Assistant Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Pediatrics |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 631
Rochester NY 14642
|
|---|
|
|
|
| Title | Assistant Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Pharmacology and Physiology |
|---|
|
|
|---|
|
| 1992 |
|
| Extended Neuroscience Research Award, The American Academy of Neurology | | 1994 |
|
| The American Federation for Clinical Research Medical Student Award | | 1994 |
|
| Dr. J. Edmund Bradley Award for Excellence in Pediatrics | | 1999 |
|
| AHA Travel Award to the 1999 Weinstein Cardiovascular Development Conference | | 2004 |
|
| The Mae Gailani Junior Faculty Award for Uncompromising Dedication to Research and Patient Care | | 2008 |
|
| Second place, Basic Cardiovascular Science Poster Competion (Research Symposium) |
Dr. Porter's laboratory studies mechanisms that control the development of the heart, concentrating on the roles played by the intracellular organelles, mitochondria. Using in vivo and in vitro mouse models of cardiac development, the lab has shown that mitochondrial structure and function changes dramatically in muscle cells as the embryonic heart develops. In particular, we have found that closure of the mitochondrial permeability transition pore, or mPTP, between the early and mid embryonic period leads to a maturation of the structure of individual mitochondria and of the mitochondrial network throughout the cell. This also leads to an activation of oxidative phosphorylation, or ATP production, by mitochondria as the heart develops. These changes also cause a drop in cellular oxidative stress due to altered mitochondrial production of reactive oxygen species, and this signals to the myocytes to undergo further differentiation.
These findings have led to additional studies. 1. Determining the mechanisms that control the activity of the mPTP. 2. Determining how the assembly of the different components of the electron transport chain are controlled by and may control the creation of the pore of the mPTP. 3. Investigating the mechanisms by which mitochondria control oxidative stress in the embryonic heart. 4. Determining oxygen levels in vivo in the embryonic and fetal heart, lungs, and brain using a novel microelectrode to determine values under normal and abnormal conditions. 5. Investigating the role that mitochondria play in regulating intracellular calcium levels in the developing heart. 6. Determining how mitochondria regulate differentiation of cardiac myocytes in the neonatal period and how oxygen levels regulate these changes and cause maturation of the infant heart.
Finally, Dr. Porter is the site principal investigator at the University of Rochester for the Pediatric Cardiac Genomics Consortium. This international, multicenter arm of the NIH Bench to Bassinet program (http://www.benchtobassinet.net/) has collects material information patients with congenital heart defects to perform genotype-phenotype correlation using advanced genetic testing. This data derived from this study is being used to discover new genes that cause human congenital heart defects and to test the pathogenesis of these genes in animal models through collaboration with the Cardiovascular Development Consortium of the Bench to Bassinet program.
These studies have been funded by the Charles H. Hood Foundation, the Children's Cardiomyopathy Foundation, the NIH, Pfizer, and the University of Rochester CTSI and are currently funded by the Founder's Affiliate of American Heart Association, the NIH, and the Strong Children's Research Center.
-
Walters AM, Porter GA, Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res. 2012 Oct 12; 111(9):1222-36.
-
Hom JR, Quintanilla RA, Hoffman DL, de Mesy Bentley KL, Molkentin JD, Sheu SS, Porter GA. The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev Cell. 2011 Sep 13; 21(3):469-78.
-
Hom J, Yu T, Yoon Y, Porter G, Sheu SS. Regulation of mitochondrial fission by intracellular Ca2+ in rat ventricular myocytes. Biochim Biophys Acta. 2010 Jun-Jul; 1797(6-7):913-21.
-
Cummings C, McCarthy P, van Hoff J, Porter G. Kawasaki disease associated with reactive hemophagocytic lymphohistiocytosis. Pediatr Infect Dis J. 2008 Dec; 27(12):1116-8.
-
Henrich WL, Clark RL, Kelly JP, Buckalew VM, Fenves A, Finn WF, Shapiro JI, Kimmel PL, Eggers P, Agodoa LE, Porter GA, Shapiro S, Toto R, Anderson T, Cupples LA, Kaufman DW. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study. J Am Soc Nephrol. 2006 May; 17(5):1472-80.
-
Lakhani SA, Masud A, Kuida K, Porter GA, Booth CJ, Mehal WZ, Inayat I, Flavell RA. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science. 2006 Feb 10; 311(5762):847-51.
-
Moltedo JM, Kopf G, Mello DM, Porter GA. Right coronary artery arising from the left ventricular outflow tract: a rare congenital anomaly of the coronary arteries. Pediatr Cardiol. 2003 Nov-Dec; 24(6):598-600.
-
Porter GA, Makuck RF, Rivkees SA. Intracellular calcium plays an essential role in cardiac development. Dev Dyn. 2003 Jun; 227(2):280-90.
-
Rentschler S, Zander J, Meyers K, France D, Levine R, Porter G, Rivkees SA, Morley GE, Fishman GI. Neuregulin-1 promotes formation of the murine cardiac conduction system. Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16):10464-9.
-
Porter GA, Makuck RF, Rivkees SA. Reduction in intracellular calcium levels inhibits myoblast differentiation. J Biol Chem. 2002 Aug 9; 277(32):28942-7.
-
Moltedo JM, Porter GA, State MW, Snyder CS. Sinus node dysfunction associated with lithium therapy in a child. Tex Heart Inst J. 2002; 29(3):200-2.
-
Porter GA, Rivkees SA. Ontogeny of humoral heart rate regulation in the embryonic mouse. Am J Physiol Regul Integr Comp Physiol. 2001 Aug; 281(2):R401-7.
-
Porter GA, Vincent MH, Penix LA. A 4-year-old girl with right elbow erythema, warmth, and induration. Curr Opin Pediatr. 1997 Feb; 9(1):31-4.
-
Porter GA, Scher MG, Resneck WG, Porter NC, Fowler VM, Bloch RJ. Two populations of beta-spectrin in rat skeletal muscle. Cell Motil Cytoskeleton. 1997; 37(1):7-19.
-
Porter GA, Dmytrenko GM, Winkelmann JC, Bloch RJ. Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle. J Cell Biol. 1992 Jun; 117(5):997-1005.
-
Milici AJ, Porter GA. Lectin and immunolabeling of microvascular endothelia. J Electron Microsc Tech. 1991 Nov; 19(3):305-15.
-
Porter GA, Palade GE, Milici AJ. Differential binding of the lectins Griffonia simplicifolia I and Lycopersicon esculentum to microvascular endothelium: organ-specific localization and partial glycoprotein characterization. Eur J Cell Biol. 1990 Feb; 51(1):85-95.
|
Porter's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
